SCHEMBL4801912

SCHEMBL4801912

Cn1cnc(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)c1-c1cc2c(N)ncnc2s1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 9/20 0.85
KDR P35968 11/20 0.61
FLT1 P17948 8/20 0.61
KIT P10721 5/20 0.61
FLT4 P35916 5/20 0.61
CSF1R P07333 5/20 0.60
FLT3 P36888 5/20 0.60
PDGFRB P09619 5/20 0.60
LCK P06239 4/20 0.60
FGFR1 P11362 4/20 0.60
FGFR3 P22607 3/20 0.60
PDGFRA P16234 2/20 0.60
FGFR2 P21802 1/20 0.60
FGFR4 P22455 1/20 0.60
AURKA O14965 4/20 0.57
RET P07949 4/20 0.57
GSK3B P49841 4/20 0.57
NTRK2 Q16620 4/20 0.57
GSK3A P49840 3/20 0.57
ROCK2 O75116 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4800594 0.92 TEK (1.00) TEKKDRFLT1KITFLT4
SCHEMBL4796015 0.84 TEK (0.86) TEKKDRFLT1KITFLT4
SCHEMBL4467818 0.81 TEK (0.83) TEKKDRFLT1KITFLT4
SCHEMBL4796059 0.77 TEK (1.00) TEKKDRFLT1KITFLT4
SCHEMBL4800669 0.77 TEK (0.72) TEKKDRFLT1KITFLT4
SCHEMBL4480247 0.77 TEK (0.85) TEKKDRFLT1KITFLT4
SCHEMBL4483938 0.76 KDR (1.00) TEKKDRFLT1KITFLT4
SCHEMBL4806052 0.76 TEK (0.79) TEKKDRFLT1KITFGFR1
SCHEMBL4471994 0.75 TEK (0.85) TEKKDRFLT1KITFLT4
SCHEMBL4466103 0.75 KDR (1.00) TEKKDRFLT1KITFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US claimed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP claimed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US claimed
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR TEK 2/4885KDR 3/4885FLT1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.